Trythree - The market cap assigned to ADO is unique to most biotechs that increase on value in anticipation of a binary outcome.
Currently investors are making investments based in ADO based on a high probability that deals with POC1 and ALERE/BBI are going to proceed. They are not the only deals in the pipeline - Many others are lined up - Just a matter of ADO applying their staff/time and prioritising to the biggest near term outcomes - Far from a company with a binary outcome with a proven tested working technology.
This will see revenues from $20-$40m pa IMO for Anteo and with costs to run the business not exceeding $5m this is why the attention.
There is also $8m cash in the bank and a very low annual burn after R&D grants of $1.5m pa
Someone came onto HC a while back and described ADO as the frothiest stock on the ASX - At the time this person was in PBT at $1.00 - I prefer by boring investment in ADO.
sp, page-47
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.002(8.33%) |
Mkt cap ! $54.31M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $12.59K | 542.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 487271 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ADO (ASX) Chart |